



Off-Label/High-Cost Specialty Review Program Drug List

Following are the drugs currently targeted in the off-label/high cost specialty review drug pharmacy initiative.

Anabolic Steroids
Anadrol [®] -50
Nandrolone
Oxandrin [®]
Analgesics
Abstral [®]
Actiq ^{®**}
Flector [®]
Fentora ^{®**}
Lazanda [®]
Onsolis [®]
Nucynta [®] ER
Antiemetic
Sancuso [®]
Antineoplastic
Arimidex [®]
Aromasin [®]
Femara [®]
Xalkori [®]
Zelboraf ^{®*}
Antivirals
Incivek [™]
Victrelis [™]
Central Nervous System Agents
Ampyra [®]
Gilenya [™]
Nuedexta [®]
Xenazine [®]

Gastrointestinal Agents
Chenodal [™]
Relistor [®]
Growth Hormone Drugs
Genotropin [®]
Humatrope [®]
Norditropin [®]
Nutropin [®]
Omnitrope [®]
Saizen [®]
Serostim [®]
Tev-Tropin [®]
Immunology & Hematology
Firazyr [®]
Gammagard Liquid
Gammaked [™]
Gamunex [®] -C
Hizentra [®]
Promacta [®]
Immunomodulators
Arcalyst [®]
Orencia [®]
Infertility Treatment
Novarel [®]
Pregnyl [®]
Osteoporosis
Forteo [®]
Miscellaneous



Off-Label/High-Cost Specialty Review Program Drug List

Xyrem [®]
Endocrinology
Cycloset [®]
Egrifta [®]
Increlex [®]
Sandostatin [®]
Sandostatin LAR [®]
Somavert [®]

*New drug added fourth-quarter 2011

**New drug added first-quarter 2012

Carbaglu [®]
Daliresp [®]
H.P. Acthar [®] gel